Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interpore Cross

This article was originally published in The Gray Sheet

Executive Summary

Spinal implant maker will acquire AOM-CDO system for placing reinforcing substances inside bony structures such as spinal vertebrae through a $21.3 mil. agreement with privately held OsteoMedix, announced May 31. Introduced in mid-2000, the minimally invasive device allows treatment of pain from vertebral compression fractures, according to Interpore. Expected to close by July 31, the deal calls for Interpore to pay $8 mil. in cash and about $2.4 mil. in Interpore stock, which closed May 30 at $5.53 per share. AOM had about $1.2 mil. in sales in 2000

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel